June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration has approved the following:
In combinat...
nivolumab
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy for adult patients with resectable non-smal...
nivolumab
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug.
Atezolizumab
Avastin (Bevacizumab)
Bevacizum...
nivolumab
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high ri...
nivolumab
August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squi...
nivolumab
Stomach Cancer Immunotherapy and Targeted Therapy
Introduction
Gastric cancer, or stomach cancer, is still one of the most virulent cancers globally, particularly in nations such as China, Japan, an...
nivolumab